•  
  •  
  •  
  •  

2025-11-02 03:41:49

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mahindra Farm Equipment Business Sells 72,071 Tractors in India during October 2025, registering a growth of 12%
  • Meet the Mahindra XEV 9S: The Big New 7-Seater Electric SUV
  • Maruti Suzuki announces sales of 220,894 units in October 2025
  • Mahindra's Trucks & Buses Business sells 2034 vehicles in October, registering a 14% growth
  • VST Tillers Tractors Ltd reports 89.36% growth in October 2025 sales

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)
  • Lupin Digital Health Launches VITALYFE™
  • Unichem Laboratories Ltd pays fine of Euro 16,753,873.41 to European Commission
  • Jenburkt Pharmaceuticals Ltd Q2 FY2025-26 PAT up at Rs. 10.16 crores
  • Veerhealth Care Limited receives new order
  • Sanofi India Limited appoints new Managing Director
  • IOL Chemicals and Pharmaceuticals Ltd receives EDQM Ceritificate of Suitability for Sitagliptin Phosphate Monohydrate
  • Sai Life Sciences set to double Process R&D capacity with new facility in Hyderabad
  • Zydus receives approval from Health Canada for Mesalamine suppositories
  • Lupin Launches Authorized Generic Version of Ravicti® in the United States
  • Laurus Labs Limited approves interim dividend of Rs. 0.80
  • Lilly and Cipla sign a distribution and promotion agreement for Yurpeak® in India
  • Caplin Steriles Ltd receives USFDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection
  • Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
  • Advagen Holdings Inc. to acquire stake in GEn1E Lifesciences Inc.
  • Innova Captab Limited updates on SMDC inspection
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL
  • Veerhealth Care Limited receives order
  • NATCO Pharma Limited - Legal update regarding Risdiplam
  • Strides and Incepta Partner to Expand Women's Health Access with WHO-Prequalified Contraceptive
  • Welcure Drugs & Pharmaceuticals Ltd allots 11,23,58,200 Bonus Equity Shares
  • Novelix Pharmaceuticals Ltd signs Technology Transfer agreement GMBU e.V., Germany for Large-Scale of Astaxanthin
  • IOL Chemicals and Pharmaceuticals Ltd receives EDQM certificate for Pantoprazole Sodium Sesquihydrate Process-III
  • AstraZeneca Pharma India Ltd to launch Sodium Zirconium Cyclosilicate powder in Nov 2025

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Mahindra Farm Equipment Business Sells 72,071 Tractors in India during October 2025, registering a growth of 12%
  • Meet the Mahindra XEV 9S: The Big New 7-Seater Electric SUV
  • Maruti Suzuki announces sales of 220,894 units in October 2025
  • Mahindra's Trucks & Buses Business sells 2034 vehicles in October, registering a 14% growth
  • VST Tillers Tractors Ltd reports 89.36% growth in October 2025 sales


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024